Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

==========================================================================================================================


Casey KA, Guo X, Smith MA, *et al*. Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE. Lupus Science, Medicine 2018;5:e000286. doi: 10.1136/lupus-2018-000286

This article has been corrected since it first published. This is to inform that co-author Wendy I White’s affiliation was addressed incorrectly. Her correct affiliation is: Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA.

Below is the updated information on the authors’ affiliation.

Kerry A Casey,1 Xiang Guo,2 Michael A Smith,1 Shiliang Wang,2 Dominic Sinibaldi,3 Miguel A Sanjuan,1 Liangwei Wang,4 Gabor G Illei,5 Wendy I White2 

1Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, Maryland, USA

2Translational Sciences, MedImmune LLC, Gaithersburg, Maryland, USA

3Research Bioinformatics, MedImmune LLC, Gaithersburg, Maryland, USA

4Biostatistics, MedImmune LLC, Gaithersburg, Maryland, USA

5Clinical Development, MedImmune LLC, Gaithersburg, Maryland, USA

*   © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: [http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0/)